Singapore: Daiichi Sankyo's pharmaceuticals subsidiary, Daiichi Sankyo Espha is all set to launch five generic products Quetiapine tablets 25 mg DSEP, Quetiapine tablets 100 mg DSEP and Quetiapine tablets 200 mg DSEP.

Quetiapine is indicated for the treatment of anti-psychosis. Espha also launched Mosapride Citrate tablets 2.5 mg DSEP, Mosapride Citrate tablets 5 mg DSEP. Mosapride Citrate is indicated for the treatment of gastroprokinetic agent. 

Daiichi Sankyo Espha was created in April 2010 to manufacture and market generic drugs and to accommodate rising demand of diverse medical needs.